How is the Pandemic Affecting MI? The Chinese Experience

ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary PCI. The whole system has established very effective protocols to minimize ischemic time from symptom onset to definite treatment in the cath lab. 

Recomendaciones de la ACC con el nuevo coronavirus

This study reports the experience in Hong Kong since January 2020, when all emergency protocols to contain the Covid-19 pandemic were activated.

This required suspending of all non-essential visits and adjusting services both for hospitalized and ambulatory patients. 

Between January 25 and February 10 2020, there were significant changes in assistance time compared against primary PCI in the same period one year earlier. 

The most affected was time between symptom onset and first medical contact. This depends mostly on patients, who will most likely wait at home for fear of catching Covid-19.


Read also Procedural Rescheduling Criteria in the Pandemic Era.


Historically, time from symptom onset to first medical contact is approximately 82 minutes, and it extended to 318 minutes during the pandemic.

We can scarcely understand the direct impact of this pandemic on the population’s health, let alone measure its indirect impact. 

To the extended onset to first contact time, we should add the extra time needed to identify patient epidemiology, contact history, symptoms, etc. 


Read also: ECS Guidelines for COVID-19 Management.


Finally, when primary PCI is indicated, we should also add extra time for safe patient transport, which involves time for all cath lab staff to wear protective gear. 

Original Title: Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China.

Reference: Chor-Cheung Frankie Tam et al. Circ Cardiovasc Qual Outcomes. 2020;13:e006631.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...